{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(15)"],"submitter":["Lv Y"],"pubmed_abstract":["The risk of venous thrombosis and mortality associated with central catheter (PICC/CICC) for malignant tumor patients is not definite. So, we carried out a systematic review and meta-analysis to evaluate it. Among patients with comparing PICC with CICC, odds ratio (OR) or risk ratio (RR) was calculated with a random effect model meta-analysis. The result of the stratification analysis of 7 studies (PICC vs CICC) supported the theory that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs. 7 of 15 studies provided the information about the compared mortality rate of the patients. The result showed that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs (OR = 0.45, 95% CI:0.32-0.62, <i>p</i> < 0.0001, I<sup>2</sup> = 0%,Tau<sup>2</sup> = 0.00). Meta-analysis of 8 studies of 2639 patients showed that pharmacological deep vein thrombosis prophylaxis drugs could decrease the risk of mortality of malignant tumor patients with CICCs (RR = 0.58, 95% CI:0.48-0.71, <i>Z</i> = 5.32, <i>p</i> < 0.0001, I<sup>2</sup> = 71%). We found that PICCs are associated with a raised risk of deep vein thrombosis, and pharmacological deep vein thrombosis prophylaxis drugs is a beneficial factor in decreasing the incidence of thrombosis, while warfarin may decrease the risk of mortality of malignant tumor patients with CICCs."],"journal":["Oncotarget"],"pagination":["12376-12388"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5844754"],"repository":["biostudies-literature"],"pubmed_title":["Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis."],"pmcid":["PMC5844754"],"pubmed_authors":["Yu L","Lv Y","Tian Y","Xu D","Ma Y","Li P","Pan B","Shang H","Wang H","Hou Y","Song J"],"additional_accession":[]},"is_claimable":false,"name":"Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis.","description":"The risk of venous thrombosis and mortality associated with central catheter (PICC/CICC) for malignant tumor patients is not definite. So, we carried out a systematic review and meta-analysis to evaluate it. Among patients with comparing PICC with CICC, odds ratio (OR) or risk ratio (RR) was calculated with a random effect model meta-analysis. The result of the stratification analysis of 7 studies (PICC vs CICC) supported the theory that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs. 7 of 15 studies provided the information about the compared mortality rate of the patients. The result showed that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs (OR = 0.45, 95% CI:0.32-0.62, <i>p</i> < 0.0001, I<sup>2</sup> = 0%,Tau<sup>2</sup> = 0.00). Meta-analysis of 8 studies of 2639 patients showed that pharmacological deep vein thrombosis prophylaxis drugs could decrease the risk of mortality of malignant tumor patients with CICCs (RR = 0.58, 95% CI:0.48-0.71, <i>Z</i> = 5.32, <i>p</i> < 0.0001, I<sup>2</sup> = 71%). We found that PICCs are associated with a raised risk of deep vein thrombosis, and pharmacological deep vein thrombosis prophylaxis drugs is a beneficial factor in decreasing the incidence of thrombosis, while warfarin may decrease the risk of mortality of malignant tumor patients with CICCs.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Feb","modification":"2026-06-18T03:52:53.243Z","creation":"2019-03-26T23:17:58Z"},"accession":"S-EPMC5844754","cross_references":{"pubmed":["29552318"],"doi":["10.18632/oncotarget.24212"]}}